LorenDPenaMD
Medical Genetics • Cincinnati, OHClinical Genetics
Assistant Professor, Pediatrics, Duke Univ Sch of Med
Are you Dr. Pena?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
Cincinnati, OH 45229Phone+1 513-636-4760Fax+1 513-636-7297
Summary
- Dr. Loren Pena, MD is a board certified medical geneticist in Cincinnati, Ohio. She is currently licensed to practice medicine in Ohio, Indiana, and Kentucky. She is an Assistant Professor at Duke Univ Sch of Med.
Education & Training
Northwestern University The Feinberg School of MedicineClass of 2004
Certifications & Licensure
OH State Medical License 2018 - 2026
KY State Medical License 2021 - 2025
IN State Medical License 2021 - 2023
NC State Medical License 2012 - 2018
IL State Medical License 2004 - 2014
American Board of Pediatrics Pediatrics
American Board of Medical Genetics and Genomics Clinical Genetics and Genomics
Publications & Presentations
PubMed
- 1 citationsInduced pluripotent stem cell (iPSC) modeling validates reduced GBE1 enzyme activity due to a novel variant, p.Ile694Asn, found in a patient with suspected glycogen st...Chie Naito, Karis Kosar, Eriko Kishimoto, Loren Pena, Yilun Huang
Molecular Genetics and Metabolism Reports. 2024-06-01 - 2 citationsLoss of TBC1D2B causes a progressive neurological disorder with gingival overgrowth.Frederike L Harms, Jessica Erin Rexach, Stephanie Efthymiou, Busra Aynekin, Hüseyin Per
European Journal of Human Genetics. 2024-05-01 - Characterization of a rare mosaic unbalanced translocation of t(3;12) in a patient with neurodevelopmental disorders.Xiaolin Hu, Elizabeth K Baker, Jodie Johnson, Stephanie Balow, Loren D M Pena
Molecular Cytogenetics. 2022-03-05
Press Mentions
Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type CJanuary 5th, 2021
Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe DiseaseMarch 3rd, 2016
